Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benfotiamine in Early Alzheimer's Disease (BenfoTeam)
NCT06223360Phase 2Active, not recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Mar 2024
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of benfotiamine in Alzheimer's disease (AD), sponsored by Weill Cornell Medicine. Started Mar 2024; status: active, not recruiting.
02
Drugs
benfotiamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06223360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06223360.